Methods for treating muscle diseases and disorders
View Patent ↗The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185 erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
1. A method of increasing myotube formation, myotube survival, muscle cell mitogenesis, or muscle cell survival in a mammal in need thereof, said method comprising administering to said mammal in an amount effective for increasing said myotube formation, myotube survival, muscle cell mitogenesis, or muscle cell survival, a polypeptide comprising an amino acid sequence of SEQ ID NO: 324.
2. The method of claim 1 , wherein said mammal has a condition which involves muscle damage.
3. The method of claim 1 , wherein said increasing results in decreased atrophy of said muscle cell.
4. The method of claim 1 , wherein said increasing results in increased muscle fibers present in said mammal.
5. The method of claim 1 , wherein said increasing is increasing the survival of said muscle cell.
6. The method of claim 1 , wherein said increasing results in increased muscle growth in said mammal.
7. The method of claim 1 , wherein said increasing results in increased muscle regeneration in said mammal.
8. The method of claim 1 , wherein said increasing is increasing the mitogenesis of said muscle cell.
9. The method of claim 1 , wherein said increasing further results in increased acetylcholine receptor systhesis.
10. The method of claim 1 , wherein said mammal is a patient lacking a neurotrophic factor.
11. The method of claim 1 , wherein said muscle cell is a myoblast.
12. The method of claim 1 , wherein said muscle cell is a satellite cell.
13. The method of claim 1 , wherein said muscle cell is in skeletal muscle.
14. The method of claim 1 , wherein said muscle cell is in cardiac muscle.
15. The method of claim 1 , wherein said muscle cell is in smooth muscle.
16. The method of claim 1 , wherein said mammal is a patient with a skeletal muscle disease.
17. The method of claim 16 , wherein said skeletal muscle disease is a myopathy.
18. The method of claim 16 , wherein said skeletal muscle disease is a dystrophy.
19. The method of claim 18 , wherein said dystrophy is Duchenne's muscular dystrophy.
20. The method of claim 18 , wherein said dystrophy is Becker's muscular dystrophy.
21. The method of claim 16 , wherein said skeletal muscle disease is a result of a neural condition.
22. The method of claim 16 , wherein said skeletal muscle disease is a traumatic injury.
23. The method of claim 21 , wherein said condition is a nerve injury.
24. The method of claim 21 , wherein said condition is a neuropathy.
25. The method of claim 1 , wherein said mammal is a patient with a cardiac muscle disorder.
26. The method of claim 25 , wherein said disorder is cardiomyopathy.
27. The method of claim 25 , wherein said disorder is ischemic damage.
28. The method of claim 25 , wherein said disorder is a degenerative congenital cardiac disease.
29. The method of claim 25 , wherein said disorder is cardiac trauma.
30. The method of claim 1 , wherein said mammal is a patient with a smooth muscle disorder.
31. The method of claim 30 , wherein said disorder is atherosclerosis and said increasing is increasing the differentiation of said muscle cell.
32. The method of claim 30 , wherein said disorder is a vascular lesion.
33. The method of claim 30 , wherein said disorder is a degenerative congenital vascular disease.
34. The method of claim 1 , wherein said muscle cell has insufficient functional acetylcholine receptors.
35. The method of claim 34 , wherein said muscle cell lacking sufficient acetylcholine receptors is in a patient with myasthenia gravis.
36. The method of claim 30 , wherein said disorder is arterial sclerosis.